Markets

Bombardier’s Global 7500 sets a new speed record on a flight from Montreal to Paris, completing the journey in 5 hours and 30 minutes at over 1,000 km/hr. The aircraft showcases its superior performance and ability to connect global cities swiftly. The Global 7500 consistently achieves impressive real-world results, solidifying its place as a premier business jet, with the Global 8000 on the horizon.

The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.

FranklinCovey is hosting a webinar on June 16, 2025, featuring Amy Edmondson, Stephen M. R. Covey, and Liz Wiseman. The discussion will delve into how leaders can thrive amidst constant disruption, addressing the leadership crisis, engagement recession, and adaptability dilemma. The event will explore strategies for navigating uncertainty and fostering successful, resilient organizations.

Upstream Bio announced promising data on verekitug, a lead candidate targeting the TSLP receptor, presented at the EAACI Congress. Modeling data suggests enhanced potency compared to tezepelumab, potentially offering a differentiated profile across inflammatory diseases like asthma, COPD, and CRSwNP. Phase 2 trials for CRSwNP are expected in Q3 2025, followed by severe asthma data in 2026’s first half.

Major discounts on premium audio products are currently available, including high-end home audio systems, noise-canceling headphones, and gaming headsets. Leading retailers offer substantial savings, further reduced by government subsidies. Featured products include the B&O Beosound A5, Sony WH-1000XM6, SteelSeries Nova Pro, and various models like Huawei FreeBuds Pro 4, offering diverse audio solutions at competitive prices for a limited time.

Phase 1b/2 trial data showed that epcoritamab combined with R-ICE achieved an 87% overall response rate and a 65% complete response rate in relapsed/refractory DLBCL patients, with 65% proceeding to ASCT. These results, presented at EHA, suggest epcoritamab may improve ASCT eligibility and represent a potential new treatment option.

Meta is acquiring a 49% non-voting stake in Scale AI for nearly $15 billion, marking a significant investment in the AI space. The deal will see Scale AI founder Alexander Wang, a former MIT dropout, join Meta. Scale AI provides crucial data annotation services for training AI models and counts major tech companies among its clients. The acquisition values Scale AI at approximately $29 billion.

Johnson & Johnson announced promising results from the Phase 2 RedirecTT-1 study, which evaluated TALVEY (talquetamab) and TECVAYLI (teclistamab) in extramedullary multiple myeloma (EMD) patients. The combination therapy showed an impressive 78.9% overall response rate. These findings suggest a potential off-the-shelf treatment approach for a patient population with limited options and significant unmet needs.

Douyin, the Chinese TikTok, removed 26 accounts impersonating the “Girl with a Carrying Pole,” a viral sensation. The platform took action after identifying accounts using her name and profile. The student, who gained fame after images of her carrying luggage went viral, confirmed she has no social media accounts and will not create any before university. She is working a part-time job to contribute to her family.

Sarepta Therapeutics is taking action to address safety concerns with its gene therapy ELEVIDYS for Duchenne muscular dystrophy after a second fatal liver failure case. The company is implementing a new immunosuppression regimen, pausing shipments for non-ambulatory patients, and halting dosing in its ENVISION study. Sarepta will discuss these developments in an investor call on June 16, 2025.